開放隅角緑内障治療法の世界市場2019-2023

◆英語タイトル:Global Open-Angle Glaucoma Therapeutics market 2019-2023
◆商品コード:IRTNTR31646
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:123
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、開放隅角緑内障治療法の世界市場について調べ、開放隅角緑内障治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、開放隅角緑内障治療法の市場規模をセグメンテーション別(製品別(PGA、ノンPGA)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は開放隅角緑内障治療法の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・開放隅角緑内障治療法の市場状況
・開放隅角緑内障治療法の市場規模
・開放隅角緑内障治療法の市場予測
・開放隅角緑内障治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(PGA、ノンPGA)
・開放隅角緑内障治療法の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Open-Angle Glaucoma Therapeutics Market: About this market

Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. Technavio’s open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.

Global Open-Angle Glaucoma Therapeutics Market: Overview

Increasing demand for combination drugs

Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.

Strategic alliances

The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global open-angle glaucoma therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.

Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

PGAs – Market size and forecast 2018-2023

Non-PGAs – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aerie Pharmaceuticals Inc.

Allergan Plc

Bausch Health Companies Inc.

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: PGAs – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: PGAs – Year-over-year growth 2019-2023 (%)

Exhibit 21: Non-PGAs – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Non-PGAs – Year-over-year growth 2019-2023 (%)

Exhibit 23: Market opportunity by product

Exhibit 24: Customer landscape

Exhibit 25: Market share by geography 2018-2023 (%)

Exhibit 26: Geographic comparison

Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Projections for glaucoma (2010, 2030, and 2050)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Population aged 65 years and above (% of total) in Asia 2017

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Some late-stage drugs in pipeline for open-angle glaucoma treatment

Exhibit 44: Some of the combination drugs

Exhibit 45: Impact of drivers and challenges

Exhibit 46: Vendor landscape

Exhibit 47: Landscape disruption

Exhibit 48: Vendors covered

Exhibit 49: Vendor classification

Exhibit 50: Market positioning of vendors

Exhibit 51: Aerie Pharmaceuticals Inc. – Vendor overview

Exhibit 52: Aerie Pharmaceuticals Inc. – Business segments

Exhibit 53: Aerie Pharmaceuticals Inc. – Organizational developments

Exhibit 54: Aerie Pharmaceuticals Inc. – Key offerings

Exhibit 55: Aerie Pharmaceuticals Inc. – Key customers

Exhibit 56: Allergan Plc – Vendor overview

Exhibit 57: Allergan Plc – Business segments

Exhibit 58: Allergan Plc – Organizational developments

Exhibit 59: Allergan Plc – Geographic focus

Exhibit 60: Allergan Plc – Segment focus

Exhibit 61: Allergan Plc – Key offerings

Exhibit 62: Allergan Plc – Key customers

Exhibit 63: Bausch Health Companies Inc. – Vendor overview

Exhibit 64: Bausch Health Companies Inc. – Product segments

Exhibit 65: Bausch Health Companies Inc. – Organizational developments

Exhibit 66: Bausch Health Companies Inc. – Geographic focus

Exhibit 67: Bausch Health Companies Inc. – Segment focus

Exhibit 68: Bausch Health Companies Inc. – Key offerings

Exhibit 69: Bausch Health Companies Inc. – Key customers

Exhibit 70: Novartis AG – Vendor overview

Exhibit 71: Novartis AG – Business segments

Exhibit 72: Novartis AG – Organizational developments

Exhibit 73: Novartis AG – Geographic focus

Exhibit 74: Novartis AG – Segment focus

Exhibit 75: Novartis AG – Key offerings

Exhibit 76: Novartis AG – Key customers

Exhibit 77: Pfizer Inc. – Vendor overview

Exhibit 78: Pfizer Inc. – Business segments

Exhibit 79: Pfizer Inc. – Organizational developments

Exhibit 80: Pfizer Inc. – Geographic focus

Exhibit 81: Pfizer Inc. – Segment focus

Exhibit 82: Pfizer Inc. – Key offerings

Exhibit 83: Pfizer Inc. – Key customers

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of market positioning of vendors



【掲載企業】

Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[開放隅角緑内障治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆